{
  "nctId": "NCT04292730",
  "briefTitle": "Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment",
  "officialTitle": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment",
  "protocolDocument": {
    "nctId": "NCT04292730",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2020-04-29",
    "uploadDate": "2020-10-22T00:43",
    "size": 1576724,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04292730/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 1113,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2020-03-15",
    "completionDate": "2020-06-26",
    "primaryCompletionDate": "2020-04-29",
    "firstSubmitDate": "2020-02-28",
    "firstPostDate": "2020-03-03"
  },
  "eligibilityCriteria": {
    "criteria": "Key Inclusion Criteria:\n\n* Willing and able to provide written informed consent prior to performing study procedures (participants ≥ 18 years of age) or assent (participants ≥ 12 and \\< 18 years of age) prior to performing study procedures. For participants ≥ 12 and \\< 18 years of age, a parent or legal guardian willing and able to provide written informed consent prior to performing study procedures\n* Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection confirmed by polymerase chain reaction (PCR) test ≤ 4 days before randomization\n* Currently hospitalized and requiring medical care for COVID-19\n* Peripheral capillary oxygen saturation (SpO2) \\> 94% on room air at screening\n* Radiographic evidence of pulmonary infiltrates\n\nKey Exclusion Criteria:\n\n* Participation in any other clinical trial of an experimental treatment for COVID-19\n* Concurrent treatment or planned concurrent treatment with other agents with actual or possible direct acting antiviral activity against SARS-CoV-2\n* Requiring mechanical ventilation at screening\n* Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 5 X upper limit of normal (ULN)\n* Creatinine clearance \\< 50 mL/min using the Cockcroft-Gault formula for participants ≥ 18 years of age {Cockcroft 1976} and Schwartz Formula for participants \\< 18 years of age\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "12 Years",
    "stdAges": [
      "CHILD",
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 11",
        "description": "Clinical status was derived from death, hospital discharge, and ordinal scale as follows: score of \"1\" was used for all days on or after the date of death; score of \"7\" was used for all days on or after discharged alive date; last available assessment for missing value. The scale is as follows: 1. Death; 2. Hospitalized, on invasive mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO); 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring low flow supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (coronavirus (COVID-19) related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care (other than per protocol remdesivir administration; 7. Not hospitalized. The odds ratio represents the odds of improvement in the ordinal scale for a RDV group relative to the SOC group.",
        "timeFrame": "Day 11"
      }
    ],
    "secondary": [
      {
        "measure": "Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)",
        "description": "TEAEs were defined as the following: any AE with an onset date on or after the study treatment start date and no later than 30 days after permanent discontinuation of study treatment and/or any AE leading to premature discontinuation of study treatment. For participants randomized to the SOC group, all AEs reported on or after the protocol-specified Day 1 visit were considered as treatment emergent.",
        "timeFrame": "First dose date up to last dose date (maximum: 10 days) plus 30 days"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 1,
      "otherCount": 0,
      "totalCount": 2
    },
    "studyDesign": {
      "phases": [
        "PHASE3"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 29,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:30:38.212Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}